Cytotoxic effects of novel polyoxotungstates and a platinum compound on human cancer cell lines

Anti-Cancer Drugs

Volumn 16, Issue 1, 2005, Pages 101-106

  Gerth, Hans U V ^a   Rompel, Annette ^a   Krebs, Bernt ^a   Boos, Joachim ^b   Lanvers Kaminsky, Claudia ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Carboplatin; Cisplatin; Ewing's sarcoma; Neuroblastoma; Polyoxoanion; Polyoxometalate

Indexed keywords

2,9 DIMETHYL 4,7 DIPHENYL 1,10 PHENANTHROLINEDICHLOROPLATIN; CARBOPLATIN; CISPLATIN; METAL DERIVATIVE; PLATINUM DERIVATIVE; POLYOXOMETALATE 1; POLYOXOMETALATE 2; POLYOXOMETALATE 3; POLYOXOMETALATE 4; POLYOXOMETALATE 5; POLYOXOMETALATE 6; POLYOXOMETALATE DERIVATIVE; POLYOXOTUNGSTATE; TUNGSTEN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; EWING SARCOMA; HUMAN; HUMAN CELL; LD 50; NEUROBLASTOMA CELL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; HUMANS; POLYMERS; TOXICITY TESTS; TUNGSTEN COMPOUNDS;

EID: 12544259703     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200501000-00015     Document Type: Article

References (32)

1. Sherman SE, Lippard SJ. Structural aspects of platinum anticancer drug interactions with DNA. Chem Rev 1987; 87:1153-1181.
2. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994; 269:787-790.
3. Toney JH, Donahue BA, Kellet PJ, Bruhn SL, Essigmann JM, Lippard SJ. Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum(II). Proc Natl Acad Sci USA 1989; 86:8328-8332.
4. Ohndorf U-M, Whitehead JP, Raju NJ, Lippard SJ. Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA Adducts. Biochemistry 1997; 36:14807-14815.
5. Grossman SA, Wharam M, Sheidler V. Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J Clin Oncol 1997; 15:2596-2603.
6. 7 with competing S-donor ligands available in the cell? Chem Rev 1999; 99:2499-2510.
7. Tallen G, Mock C, Gangopadhyay SB, Kangarloo B, Krebs B, Wolff JEA. Overcoming cisplatin resistance: design of novel hydrophobic platinum compounds. Anticancer Res 2000; 20:445-450.
8. Möller N, Kangarloo BS, Puscasu I, Mock C, Krebs B, Wolff JEA. Rational design of platinum chemotherapeutic drugs: hydrophobicity increases cytotoxicity. Anticancer Res 2000; 20:4435-4440.
9. Zlatanova J, Yaneva J, Leuba SH. Proteins that specifically recognize cisplatin-damaged DNA: a clue to anticancer activity of cisplatin. FASEB J 1998; 12:791-799.
10. Rauterkus MJ, Krebs B. Platinum(II) and palladium(II) complexes with a highly tensed phenanthroline ligand system. J Chem Soc Dalton Trans, in preparation; CCDC 193826.
11. Hill CL. Introduction: polyoxometalates-multicomponent molecular vehicles to probe fundamental issues and practical problems. Chem Rev 1998; 98:1-2.
12. Jasmin C, Raybaud N, Chermann JC, Haapala D, Sinoussi F, Loustau VB, et al. In vitro effects of silicotungstate on some RNA viruses. Biomedicine 1973; 18:319-327.
13. Jasmin C, Chermann JC, Herve G, Teze A, Souchay P, Boy-Loustau C, et al. In vivo inhibition of murine leukemia and sarcoma viruses by the heteropolyanion 5-tungsto-2-antimoniate. J Natl Cancer Inst 1974; 53: 469-474.
14. Moskovitz BL. Clinical trial of tolerance of HPA-23 in patients with acquired rnmune deficiency syndrome. Antimicrob Ag Chemother 1988; 32: 1300-1303.
15. Burgard M, Sansonetti P, Vittecoq D, Descamps P, Guetard D, Herson S, et al. Lack of HPA-23 antiviral activity in HIV-infected patients without AIDS. AIDS 1989; 3:665-668.
16. 2O. Chem Res Chin Univ 2000; 17: 356-361.
17. Wolff JEA, Pascha KP, Poppenborg H, Anderson R, Thulig CC, Krebs B. Polyoxoanions are cytotoxic to malignant glioma cells. Anticancer Drugs 1998; 9:803-807.
18. Wang XH, Liu JF. Synthesis and characterization of organotin substituted heteropolytungstophosphates and their biological activity. J Coord Chem 2000; 51:73-82.
19. 5). J Inorg Biochem 2003; 94:279-284.
20. Fujita H, Fujita T, Sakurai T, Yamase T, Seto Y. Antitumor activity of new antitumor substance, polyoxomolybdate, against several human cancers in athymic nude Mice. Tohoku Exp Med 1992; 168:421-426.
21. Mukherjee HN. Treatment of cancer of the intestinal tract with a complex compound of phosphotungstic phosphomolybdic acids and caffaine. J Indian Med Ass 1965; 44:477.
22. Droste E, Piepenbrink M, Vollmer G, Krebs B. Novel kegginstannato(II) tungstates with lone-pair assembling atoms. Syntheses, crystal structure and spectroscopic studies. C R Acad Sci Paris Ser II 2000; C3:205-210.
23. Bösing M, Nöh A, Loose I, Krebs B. Highly efficient catalysts in directed oxygen transfer processes: synthesis, structures of novel manganese-containing heteropolyanions and applications in regioselective epoxidation of cienes with hydrogen peroxide. J Am Chem Soc 1998; 120:7252-7259.
24. 20-Typs mit Antimon(III) als Heteroatom. Z Anorg Allg Chem 2002; 628:1187.
25. Drewes D, Limanski EM, Piepenbrink M, Krebs B. Neue Heteropolyanionen des Wolframs mit Vanadium (IV) als Heteroatom. Z Anorg Allg Chem 2004; 630:58-62.
26. Drewes D, Limanski EM, Piepenbrink M, Krebs B. Manganese substituted polyoxometalates as efficient oxidation catalysts. Eur J Inorg Chem, in preparation; CSD 391145.
27. Limanski EM, Drewes D, Krebs B. Synthesis and X-ray characterization of Novel polymeric polyoxometalates. Inorg Chim Acta, in preparation; CSD 413336.
28. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989; 119:203-210.
29. Eastman A. Cisplatin. Chemistry and biochemistry of a leading anticancer drug. Helv Chim Acta 1999:111-134
30. Rhule JT, Hill CL, Judd DA, Schinazi RF. Polyoxometalates in medicine. Chem Rev 1998; 98:327-357.
31. Peng J, Li W, Wang E, Zhao X, Huang B. Polyoxometalate coordinated phosphato complexes: a possible model reaction for POM-nucleotide nteraction. Inorg Chem Commun 2000; 3:615-616.
32. Shigeta S, Mori S, Kodama E, Kodama J, Takahashi K, Jamase T. Broad spectrum anti-RNA virus activities of titanium and vanadium substituted polyoxotungstates. Antiviral Res 2003; 58: 265-271.